iProtics is revolutionizing the treatment of cancer and auto-immune disorders.
iProtics has raised $383K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2024.
iProtics's investors include UNIIQ.
iProtics is headquartered in Leiden, The Netherlands.
iProtics is revolutionizing the treatment of cancer and auto-immune disorders.
iProtics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"iProtics — Funding & Investors." VCBacked, October 9, 2024, https://www.vcbacked.co/company/iprotics. Accessed August 16, 2026.
VCBacked. (2024). iProtics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/iprotics
{{cite web |title=iProtics — Funding & Investors |url=https://www.vcbacked.co/company/iprotics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated